Table 2

Demographic, histopathological data, and aberrant protein expression in 18 patients with IPMT

Case	Sex/Age	Histopathology	Distribution	Margins	Outcome	p53	p16	Smad4	Cyclin D1	p21	p27
MDT, main duct tumour; BDT, branch duct tumour; IPMT, intraductal papillary mucinous tumour; IPMC, intraductal papillary mucinous carcinoma; NED, no evidence of disease.
•Aberrant expression.
1	F/65	Adenoma	MDT	Clear	NED 21 months
2	M/65	Borderline	MDT	Clear	NED 7 months
3	M/85	Borderline	MDT	Clear	NED 4 months						•
4	M/63	Borderline	MDT+BDT	Involved IPMT	NED 40 months					•
5	F/60	Borderline	MDT	Clear	NED 11 months					•
6	M/68	Borderline	MDT+BDT	Clear	NED 31 months				•
7	M/65	Borderline	BDT	Involved IPMT	NED 20 months				•		•
8	M/66	Borderline	MDT	Clear	NED 22 months	•					•
9	F/68	Borderline	MDT+BDT	Clear	NED 32 months	•			•
10	M/80	Borderline	MDT	Clear	NED 78 months	•	•		•
11	M/47	IPMC	MDT	Clear	NED 4 months	•	•
12	M/72	IPMC	MDT+BDT	Clear	NED 23 months		•
13	M/54	IPMC	MDT+BDT	Involved IPMC	NED 11 months		•		•
14	M/61	IPMC	MDT	Clear	NED 78 months	•	•		•	•
15	M/50	IPMC+invasion (mucinus non-cystic)	BDT	Involved invasive carcinoma	Recurrence 10 months		•			•
16	F/71	IPMC+invasion (tubular)	MDT	Clear	Deceased 9 months	•	•	•	•	•
17	M/79	IPMC+invasion (tubular)	MDT	Involved invasive carcinoma	Deceased 21 months	•	•	•	•	•
18	F/56	IPMC+invasion (tubular)	MDT	Involved invasive carcinoma	Deceased 19 months	•	•	•	•	•